350 related articles for article (PubMed ID: 31127325)
1. Clinical risk factors of stroke and major bleeding in patients with non-valvular atrial fibrillation under rivaroxaban: the EXPAND Study sub-analysis.
Sakuma I; Uchiyama S; Atarashi H; Inoue H; Kitazono T; Yamashita T; Shimizu W; Ikeda T; Kamouchi M; Kaikita K; Fukuda K; Origasa H; Shimokawa H
Heart Vessels; 2019 Nov; 34(11):1839-1851. PubMed ID: 31127325
[TBL] [Abstract][Full Text] [Related]
2. The EXPAND study: Efficacy and safety of rivaroxaban in Japanese patients with non-valvular atrial fibrillation.
Shimokawa H; Yamashita T; Uchiyama S; Kitazono T; Shimizu W; Ikeda T; Kamouchi M; Kaikita K; Fukuda K; Origasa H; Sakuma I; Saku K; Okumura Y; Nakamura Y; Morimoto H; Matsumoto N; Tsuchida A; Ako J; Sugishita N; Shimizu S; Atarashi H; Inoue H
Int J Cardiol; 2018 May; 258():126-132. PubMed ID: 29429636
[TBL] [Abstract][Full Text] [Related]
3. Real-World Outcomes of Rivaroxaban Treatment in Patients with Both Nonvalvular Atrial Fibrillation and a History of Ischemic Stroke/Transient Ischemic Attack.
Minematsu K; Ikeda T; Ogawa S; Kitazono T; Nakagawara J; Miyamoto S; Murakawa Y; Takeichi M; Kidani Y; Okayama Y; Sunaya T; Sato S; Yamanaka S
Cerebrovasc Dis; 2019; 48(1-2):53-60. PubMed ID: 31578012
[TBL] [Abstract][Full Text] [Related]
4. CHA
Peacock WF; Tamayo S; Patel M; Sicignano N; Hopf KP; Yuan Z
Ann Emerg Med; 2017 May; 69(5):541-550.e1. PubMed ID: 27913059
[TBL] [Abstract][Full Text] [Related]
5. Real-world outcomes of rivaroxaban treatment in patients with nonvalvular atrial fibrillation and worsening renal function.
Nakagawara J; Ikeda T; Ogawa S; Kitazono T; Minematsu K; Miyamoto S; Murakawa Y; Takeichi M; Kidani Y; Okayama Y; Sunaya T; Sato S; Yamanaka S
J Cardiol; 2019 Dec; 74(6):501-506. PubMed ID: 31371191
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1.
Coleman CI; Turpie AGG; Bunz TJ; Eriksson D; Sood NA; Baker WL
Eur Heart J Cardiovasc Pharmacother; 2019 Apr; 5(2):64-69. PubMed ID: 30020424
[TBL] [Abstract][Full Text] [Related]
7. Clinical Risk Factors of Thromboembolic and Major Bleeding Events for Patients with Atrial Fibrillation Treated with Rivaroxaban in Japan.
Miyamoto S; Ikeda T; Ogawa S; Kitazono T; Nakagawara J; Minematsu K; Murakawa Y; Iwashiro S; Takeichi M; Kidani Y; Okayama Y; Sunaya T; Sato S; Yamanaka S
J Stroke Cerebrovasc Dis; 2020 Apr; 29(4):104584. PubMed ID: 31983518
[TBL] [Abstract][Full Text] [Related]
8. Real-world outcomes of rivaroxaban treatment in elderly Japanese patients with nonvalvular atrial fibrillation.
Kitazono T; Ikeda T; Ogawa S; Nakagawara J; Minematsu K; Miyamoto S; Murakawa Y; Cavaliere M; Hayashi Y; Kidani Y; Okayama Y; Sunaya T; Sato S; Yamanaka S
Heart Vessels; 2020 Mar; 35(3):399-408. PubMed ID: 31492970
[TBL] [Abstract][Full Text] [Related]
9. XaMINA: A Real-World, Prospective, Observational Study of Treatment-Naïve Patients Treated with Rivaroxaban for Stroke Prevention in Atrial Fibrillation in Asia.
Liu PY; Choi EK; Kim TS; Kuo JY; Lee JM; On YK; Park SW; Park HW; Shin DG; Wang L; Yen HW; Lee MH;
Adv Ther; 2022 Jul; 39(7):3316-3333. PubMed ID: 35616848
[TBL] [Abstract][Full Text] [Related]
10. Impact of body mass index on real-world outcomes of rivaroxaban treatment in Japanese patients with non-valvular atrial fibrillation.
Murakawa Y; Ikeda T; Ogawa S; Kitazono T; Nakagawara J; Minematsu K; Miyamoto S; Hayashi Y; Kidani Y; Okayama Y; Sunaya T; Sato S; Yamanaka S
Heart Vessels; 2020 Aug; 35(8):1125-1134. PubMed ID: 32253531
[TBL] [Abstract][Full Text] [Related]
11. Bleeding outcomes associated with rivaroxaban and dabigatran in patients treated for atrial fibrillation: a systematic review and meta-analysis.
Bundhun PK; Soogund MZ; Teeluck AR; Pursun M; Bhurtu A; Huang WQ
BMC Cardiovasc Disord; 2017 Jan; 17(1):15. PubMed ID: 28056795
[TBL] [Abstract][Full Text] [Related]
12. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
[TBL] [Abstract][Full Text] [Related]
13. Incidence of major and clinically relevant non-major bleeding in patients prescribed rivaroxaban for stroke prevention in non-valvular atrial fibrillation in secondary care: Results from the Rivaroxaban Observational Safety Evaluation (ROSE) study.
Evans A; Davies M; Osborne V; Roy D; Shakir S
PLoS One; 2020; 15(10):e0240489. PubMed ID: 33035259
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the Incidence of Major Bleeding With Rivaroxaban Use Among Nonvalvular Atrial Fibrillation Patients With Versus Without Diabetes Mellitus.
Peacock WF; Tamayo S; Sicignano N; Hopf KP; Yuan Z; Patel M
Am J Cardiol; 2017 Mar; 119(5):753-759. PubMed ID: 28081941
[TBL] [Abstract][Full Text] [Related]
15. Impact of renal function deterioration on adverse events during anticoagulation therapy using non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.
Miyamoto K; Aiba T; Arihiro S; Watanabe M; Kokubo Y; Ishibashi K; Hirose S; Wada M; Nakajima I; Okamura H; Noda T; Nagatsuka K; Noguchi T; Anzai T; Yasuda S; Ogawa H; Kamakura S; Shimizu W; Miyamoto Y; Toyoda K; Kusano K
Heart Vessels; 2016 Aug; 31(8):1327-36. PubMed ID: 26276272
[TBL] [Abstract][Full Text] [Related]
16. Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48.
Berg DD; Ruff CT; Jarolim P; Giugliano RP; Nordio F; Lanz HJ; Mercuri MF; Antman EM; Braunwald E; Morrow DA
Circulation; 2019 Feb; 139(6):760-771. PubMed ID: 30586727
[TBL] [Abstract][Full Text] [Related]
17. Primary and secondary prevention of stroke and systemic embolism with rivaroxaban in patients with non-valvular atrial fibrillation : Sub-analysis of the EXPAND Study.
Uchiyama S; Atarashi H; Inoue H; Kitazono T; Yamashita T; Shimizu W; Ikeda T; Kamouchi M; Kaikita K; Fukuda K; Origasa H; Shimokawa H
Heart Vessels; 2019 Jan; 34(1):141-150. PubMed ID: 29980835
[TBL] [Abstract][Full Text] [Related]
18. Outcomes associated with under-dosing of rivaroxaban for management of non-valvular atrial fibrillation in real-world Japanese clinical settings.
Ikeda T; Ogawa S; Kitazono T; Nakagawara J; Minematsu K; Miyamoto S; Murakawa Y; Iwashiro S; Kidani Y; Okayama Y; Sunaya T; Sato S; Yamanaka S
J Thromb Thrombolysis; 2019 Nov; 48(4):653-660. PubMed ID: 31432451
[TBL] [Abstract][Full Text] [Related]
19. Real-world outcomes of the Xarelto Post-Authorization Safety & Effectiveness Study in Japanese Patients with Atrial Fibrillation (XAPASS).
Ikeda T; Ogawa S; Kitazono T; Nakagawara J; Minematsu K; Miyamoto S; Murakawa Y; Takeichi M; Ohashi Y; Okayama Y; Sunaya T; Yamanaka S
J Cardiol; 2019 Jul; 74(1):60-66. PubMed ID: 30745002
[TBL] [Abstract][Full Text] [Related]
20. Study Design and Baseline Characteristics of the EXPAND Study: Evaluation of Effectiveness and Safety of Xa Inhibitor, Rivaroxaban for the Prevention of Stroke and Systemic Embolism in a Nationwide Cohort of Japanese Patients Diagnosed as Non-Valvular Atrial Fibrillation.
Ikeda T; Atarashi H; Inoue H; Uchiyama S; Kitazono T; Yamashita T; Shimizu W; Kamouchi M; Kaikita K; Fukuda K; Origasa H; Sakuma I; Saku K; Okumura Y; Nakamura Y; Morimoto H; Matsumoto N; Tsuchida A; Ako J; Sugishita N; Shimizu S; Shimokawa H
Tohoku J Exp Med; 2016 Dec; 240(4):259-268. PubMed ID: 27904005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]